Lung cancer: open trials in Singapore

43 open trials have a site in Singapore. Registry data; only the trial team decides who can take part.

NCT04198766
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Trial Treatment · Phase 1/2 · Inhibrx Biosciences, Inc
Icon Cancer Centre Farrer Park, Singapore · Icon Cancer Centre - Mount Alvernia, Singapore · Curie Oncology, Singapore
Registry updated 2026-11-06
NCT05384626
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Trial Treatment · Phase 1/2 · Nuvalent Inc.
National Cancer Centre Singapore, Singapore · National University Hospital, Singapore
Registry updated 2026-11-06
NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Trial Treatment · Phase 3 · Amgen
National University Hospital, Singapore · Tan Tock Seng Hospital, Singapore
Registry updated 2026-11-06
NCT06881784
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Trial Treatment · Phase 3 · Revolution Medicines, Inc.
National Cancer Centre Singapore, Singapore · Icon Cancer Centre, Singapore · National University Hospital, Singapore
Registry updated 2026-11-06
NCT07699328
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Trial Treatment · Phase 1/2 · Voronoi, Inc
Tan Tock Seng Hospital, Singapore · National Cancer Centre Singapore, Singapore
Registry updated 2026-11-06
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Hoffmann-La Roche
National University Hospital, Singapore · National Cancer Centre, Singapore
Registry updated 2026-11-05
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
National Cancer Centre Singapore, Singapore · Tan Tock Seng Hospital, Singapore
Registry updated 2026-11-05
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 3 · Bayer
OncoCare Cancer Centre | Gleneagles Medical Centre, Singapore · Tan Tock Seng Hospital, Singapore · National Cancer Center Singapore - Oncology Department, Singapore · Curie Oncology (Farrer), Singapore · Raffles Cancer Centre, Singapore
Registry updated 2026-11-04
NCT06706076
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Trial Treatment · Phase 1/2 · BlossomHill Therapeutics
National University Hospital, Kent Ridge · National Cancer Centre Singapore, Singapore
Registry updated 2026-11-04
NCT07185997
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Trial Treatment · Phase 3 · ArriVent BioPharma, Inc.
National Cancer Centre Singapore, Singapore · Curie Oncology (Farrer), Singapore · Tan Tok Seng Hospital, Singapore
Registry updated 2026-11-02
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Trial Treatment · Phase 3 · Boehringer Ingelheim
National Cancer Centre Singapore, Singapore
Registry updated 2026-11-02
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.
Raffles Hospital, Singapore · Curie Oncology - Farrer - 10-05, Singapore
Registry updated 2026-10-30
NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
National Cancer Centre Singapore (Site 2251), Singapore · Tan Tock Seng Hospital (Site 2252), Singapore
Registry updated 2026-10-30
NCT04886804
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Trial Treatment · Phase 1 · Boehringer Ingelheim
National University Hospital-Singapore-22806, Singapore · National Cancer Centre Singapore, Singapore
Registry updated 2026-10-28
NCT06747585
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Trial Treatment · Phase 1/2 · Alentis Therapeutics AG
National University Cancer Institue, Singapore · National Cancer Centre Singapore, Singapore
Registry updated 2026-10-28
NCT06914128
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Trial Treatment · Phase 1/2 · Bayer
National Cancer Center Singapore - Oncology Department, Singapore · National University Hospital Medical Centre, Singapore · Icon Cancer Centre, Singapore
Registry updated 2026-10-28
NCT06931717
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Trial Treatment · Phase 3 · ETOP IBCSG Partners Foundation
National University Hospital, Singapore
Registry updated 2026-10-28
NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Trial Treatment · Phase 3 · Boehringer Ingelheim
National Cancer Centre Singapore, Singapore · Tan Tock Seng Hospital, Singapore
Registry updated 2026-10-28
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Singapore · National Cancer Centre Singapore, Singapore
Registry updated 2026-10-23
NCT06568939
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 2 · AbbVie
National University Hospital /ID# 271700, Singapore · National Cancer Centre Singapore /ID# 271499, Singapore
Registry updated 2026-10-22
NCT05099172
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 1/2 · Bayer
National University Hospital Medical Centre, Singapore · Curie Oncology | Mount Elizabeth Novena, Singapore · National Cancer Center Singapore - Oncology Department, Singapore
Registry updated 2026-10-21
NCT07564401
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Trial Treatment · Phase 1/2 · Novartis Pharmaceuticals
Singapore
Registry updated 2026-10-19
NCT07098338
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 2 · AstraZeneca
Singapore
Registry updated 2026-10-15
NCT07128199
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Trial Treatment · Phase 3 · Taiho Oncology, Inc.
Curie Oncology - Farrer - 10-05, Singapore · P.H Feng Research Centre, Singapore · National Cancer Centre Singapore, Singapore · Tan Tock Seng Hospital, Singapore
Registry updated 2026-10-13
NCT07100080
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Trial Treatment · Phase 2/3 · Bristol-Myers Squibb
Tan Tock Seng Hospital, Singapore · National Cancer Centre Singapore, Singapore
Registry updated 2026-10-09

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error